Due to COVID-19, along with just about everyone else, tens of thousands of pharmaceutical representatives are now “working from home”. This has created an engagement void that drug makers are now filling with websites, apps and other digital tools, in an effort to maintain some semblance of interaction with the doctors who prescribe their treatments. How do we make sense of this new digital ecosystem?